New patent granted in dry eye disease
H4 Orphan Pharma is pleased to inform you of the validation of a new patent for its active ingredient 554-002 in dry eye and allergic eye in Japan. This patent…
H4 Orphan Pharma and TheraVet join forces to accelerate the development of an innovative treatment for pulmonary fibrosis
H4 Orphan is pleased to announce a strategic agreement between TheraVet and H4 Orphan Pharma whereby H4 Orphan Pharma's lead clinical programme in idiopathic pulmonary fibrosis is contributed to TheraVet…